Aptose Biosciences Inc (APS)

1.09
-0.04(-3.54%)
  • Volume:
    2,050
  • Bid/Ask:
    1.09/1.12
  • Day's Range:
    1.09 - 1.15

APS Overview

Prev. Close
1.13
Day's Range
1.09-1.15
Revenue
-
Open
1.15
52 wk Range
0.9-3.91
EPS
-0.636
Volume
2,050
Market Cap
100.59M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
15,135
P/E Ratio
-1.35
Beta
1.41
1-Year Change
-65.06%
Shares Outstanding
92,283,876
Next Earnings Date
Nov 08, 2022
What is your sentiment on Aptose Biosciences?
or
Market is currently closed. Voting is open during market hours.

Aptose Biosciences Inc News

Welcome to Your News Upgrade

Be the First to Know and Act on Market Moving News.

Welcome to Your News Upgrade

Aptose Biosciences Inc Analysis

Aptose Biosciences Inc Company Profile

Aptose Biosciences Inc Company Profile

Employees
0
Market
Canada
  • Type:Equity
  • Market:Canada
  • ISIN:CA03835T2002
  • CUSIP:03835T200

Aptose Biosciences Inc. is a Canada-based clinical stage precision oncology biotechnology company. It is engaged in advancing kinase inhibitors to treat unmet medical needs in life-threatening cancers, such as acute myeloid leukemia (AML), certain B-cell malignancies, high-risk myelodysplastic syndrome (MDS) and other hematologic malignancies. Its HM43239 is being evaluated in an international Phase I/II study in patients with relapsed or refractory AML. Its Luxeptinib is being evaluated in a Phase I a/b trial in patients with relapsed or refractory B cell malignancies, and in a separate Phase I a/b trial in patients with relapsed or refractory AML or high-risk MDS. Its APTO-253 is a small molecule MYC oncogene inhibitor at the Phase Ia/b clinical trial stage of development for the treatment of patients with relapsed or refractory (R/R) blood cancers, including AML and high-risk MDS. Its APL-581 is a dual bromodomain and extra-terminal domain motif protein and kinase inhibitor program.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesSellNeutralNeutralSellStrong Sell
Technical IndicatorsStrong SellStrong SellSellStrong BuyStrong Sell
SummaryStrong SellSellNeutralNeutralStrong Sell
  • any new ?
    0
    • Is it time to buy this Stock.....?
      0
      • Any thoughts on this?
        0
        • 2021.06.14. Bought again @ 3.81 after the dive.
          0
          • 2021.06.08. Bought 3.80 and sold 6.80 in March 2021
            0
            • target at about 11.40$
              1
              • 100% BUY! Check it out!
                1
                • U wouldve made 5.78% on your money! 😃
                  1
              • Encouraging newsChairman, President and Chief Executive Officer. “We are encouraged by the continued increase in plasma exposure, and we hope the current and future dose levels will deliver formal responses to these deeply relapsed or refractory CLL patients. In AML, we are pleased by the observation of an anti-leukemic blast reduction from 93% to 10% in one of our first patients who was heavily pretreated with several consecutive FLT3 inhibitors. For APTO-253, we continue to escalate the dose and observe MYC repression, suggesting future potential for broad anti-cancer activity. We are pleased by such indicators of activity from both CG-806 and APTO-253, and we look forward to providing further updates in the first half of 2021 and at the Annual EHA Meeting 2021.”
                2
                • APTO is a LT Stock, I see good things ahead as they get positive results from their studies..I have a good feeling about it, loaded up for LT at this price range
                  1
                  • I got in at 3.98, lets see how will it go
                    1